Parenteral manufacturer will add new capacity to its Wilson County operations.
Specializing in products and technologies for infusion, transfusion and clinical nutrition, Fresenius Kabi recently publicized that it intends to expand its manufacturing operations in Wilson County, North Carolina. According to Governor Roy Cooper, the expansion will bring hundreds of new jobs and more than $100 million in investment to Wilson, where Fresenius currently employs approximately 100 people.
Fresenius Kabi confirmed plans to expand the current pharmaceutical production facilities in Wilson, constructing a new manufacturing facility. Senior VP, Global Operations for Fresenius Kabi North America, Steven R. Nowicki, said “Our strategy is to produce in the U.S. and to invest in products and operations that meet important customer needs while helping make health care more accessible for patients. We’re pleased to continue this approach at our site in North Carolina.”
The expansion will add a variety of new job functions including production specialists, engineers, scientists and managers. “Manufacturing represents 22 % of our state’s economic output and we’re one of the country’s largest centers for biotechnology,” said North Carolina Commerce Secretary Anthony M. Copeland. “We congratulate Fresenius Kabi for this decision, which helps North Carolina maintain its leadership in manufacturing and the life sciences.”
According to the announcement, a Development Investment Grant (JDIG) approved by the state’s Economic Investment Committee supports the expansion. Fresenius said the expansion project, facilitated over the course of the 12-year term of the grant, will grow the state’s economy by an estimated $853 million.
“Under the terms of the grant, the company agrees to create 445 jobs over five years,” read the statement on the expansion. “Using a formula that takes into account the new tax revenues generated by the new jobs, the JDIG agreement then authorizes the potential reimbursement to the company of up to $7.2 million, spread over 12 years.”
